USPTO serial 87949621
BAUSCH HEALTH
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- DELGIZZI, RONALD ERNEST
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with BAUSCH HEALTH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Robert J. Gorman
1400 N. Goodman StreetLaw DepartmentRochester, NY 14609Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | Non-medicated mouth care preparations, namely, non-medicated mouthwash; Non-medicated skin care preparations; Non-medicated skin care preparations, namely, cleansers, exfoliants, moisturizers, sunblocks, skin care cream, skin lotion; Non-medicated cosmetic creams and lotions, namely, skin lightening preparations; Non-medicated anti-aging preparations, namely, anti-aging cream, anti-wrinkle creams and anti-aging lotion; Silicone treated polishing tissues to be used in the polishing of glass and other vitreous surfaces; impregnated cleaning, dusting or polishing cloths, namely, cloths impregnated with a detergent for cleaning; Cosmetics; Oil absorbing polymer sold as a component of non-medicated skin treatment preparations; Body powder; Hair shampoo; Non-medicated dandruff hair shampoo; Body wash; Nail care preparations; Nail varnishes and polishes; Cuticle conditioners; Cleaning products, namely, cleaning solution in a spray bottle for use on electronic equipment containing a monitor or display screen; Impregnated cleaning cloths, namely, cloths pre- moistened with a cleaning agent, for use on electronic equipment containing a monitor or display screen | ACTIVE | — |
| 005 | Antifungal preparations; Topical anti-itch preparations, namely, lotions, creams, ointments, gels; Contact lens solutions; Contact lens disinfectants; Contact lens wetting solutions; Ophthalmic solutions and preparations for the eye; Disinfecting and saline solution for medical purposes for contact lenses; chemical preparation sold as a component of contact lens solutions; rewetting drops for use with contact lenses; Eye drops; ophthalmic preparations, namely, impregnated strips for applying preparations to the eye; pharmaceutical preparation for injection into the eye; pharmaceuticals, namely, eye drops, solutions, gels and ointments used for the treatment of eye conditions such as dry eyes, allergies, inflammation and redness; pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; pharmaceutical preparations for use with contact lenses and kits containing said preparations; Pharmaceutical preparations for ocular or intraocular surgery; Ophthalmic pharmaceutical preparations and substances; ophthalmic preparations and pharmaceutical substances for the treatment of ophthalmic disorders; viscoelastic eye lubricant; Pharmaceutical preparations and substances for the treatment of eye diseases, disorders and conditions; Ophthalmic pharmaceuticals, namely, solutions and ointments for the treatment of dry eye symptoms; hypertonic ophthalmic solution drug product; ophthalmic pharmaceutical preparation, namely, silicone oil used in ophthalmic surgical procedures; Intra-vitreal implants containing a pharmaceutical preparation for the treatment of eye and vision conditions; Pharmaceuticals, namely, ophthalmic solutions for the treatment of glaucoma and ocular hypertension; sterile sodium hyaluronate solution in the nature of a pharmaceutical preparation for use in the eyes; Pharmaceutical preparations and substances for use in dermatology and skin disorders, skin conditions, acne, fungal infections and skin care; Acne medications and acne treatment preparations; pharmaceutical preparations and substances for the prevention and treatment of skin care disorders, conditions, injuries, illnesses and ailments; pharmaceutical preparations and substances for the prevention and treatment of dermatological disorders and diseases and dermatitis; dermatological and skin care pharmaceutical preparations and substances; pharmaceutical preparations and substances for the treatment of ophthalmological, ocular and eye diseases and disorders; medicinal preparation containing sodium propyl-methyl-carbinyl allyl barbiturate and useful as hypnotics; vitamin and mineral supplements; antibiotics; medicated facial wash, skin care creams and lotions; medicated skin care preparations; Food supplements, vitamin and mineral supplements and herbal supplements in tablet, capsule, liquid or powder form; Pharmaceutical preparations for the treatment, prevention and/or alleviation of disorders of the gastrointestinal tract; pharmaceutical preparations for the treatment of chorea; pharmaceutical preparations for the treatment of hyperkinetic movement disorders; pharmaceutical preparations for the treatment of neurological disorders and movement disorders; Pharmaceutical preparations, namely, pharmaceutical preparations and substances for the treatment of skin disorders, diseases, conditions and ailments; pharmaceutical preparations and substances for the treatment of eye disorders, diseases, conditions and ailments; pharmaceutical preparations and products for ophthalmological use; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety, depression, depressive disorders and mental illness; tranquilizers and sedatives; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardiovascular system; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations, namely, immunomodulators; anticholinesterase preparation for the prevention, treatment and alleviation of neurological disorders; Vaginally administered metronidazole gel for use in the treatment of vaginal disorders; intravenous preparations for the treatment of hyperammonemia of all origins; Skin patch for delivering nitroglycerin to a medical patient; anticonvulsants; pharmaceutical preparations for treating inflammatory disorders such as psoriasis; pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, anti-inflammatories and pain relief medication; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances for the treatment of fungal infections, onychomycosis, tinea infections, and similar diseases of the skin and nails; pharmaceutical preparations and substances for use in dermatological conditions; Topical anti-itch preparations for use on humans for the treatment of skin disorders and skin rashes; Medicated skin care products, namely, medicated skin lotion; Medicated body lotion; Nutritionally fortified soft chews for use as nutritional supplements, probiotic compositions for use as nutritional supplements, multivitamin preparations, food supplements, nutritional supplements, vitamins, natural herbal supplements, mineral supplements, protein supplements, all of the foregoing goods being medicated and containing natural ingredients; Pharmaceutical preparations and substances for the treatment of epilepsy, seizures and neurological and psychological diseases and disorders; Pharmaceutical products, namely, viscoelastic solutions for intraocular use; Medicines and medicinal preparations for human purposes, namely, to support treatment of hemorrhoids, chronic venous insufficiency and lymphedema; sanitary preparations for medical purposes; pharmaceutical preparations to support treatment of hemorrhoids, chronic venous insufficiency and lymphedema; homeopathic pharmaceutics for use in support treatment of hemorrhoids, chronic venous insufficiency and lymphedema and vitamin preparations, all in the form of tablets or powder or soft gelatin capsules or hard gelatin capsules; homeopathic preparations, namely, homeopathic preparations containing herbs for medical purposes; therapeutic medicinal teas; dietetic food preparations adapted for medical purposes; food supplements for medical purposes, namely, food supplements for enhancing the immune system's resistance and improving bodily health; Pharmaceutical preparations, namely, a topical cream for the treatment of pre-cancerous skin lesions; pharmaceutical preparations and substances for the prevention and treatment of disorders, diseases, conditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention and treatment of hypertension; Pharmaceutical preparations for the treatment of nausea, emesis; Acetaminophen sold as an analgesic for the relief of pain; medicated skin care preparations for use in treating scars and damaged skin; topical gel for medical and therapeutic use in the treatment of scars and damaged skin; antiviral pharmaceutical compounds; antiobesity agent in the nature of a pharmaceutical preparation; Dermotherapeutic preparation for use in the treatment of obesity; Pharmaceutical products, namely, lipid and triglyceride reducing agents for use in the treatment of cardiovascular and heart disease; Diuretic preparations; Blend of ingredients sold as an integral component of medicated topical anti-itch preparations; Pharmaceutical preparations for the treatment of oral mucositis and xerostomia; pharmaceutical preparations and substances for the treatment of eye disorders, diseases, conditions and ailments; pharmaceutical preparations and products for ophthalmological use; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardiovascular system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Parkinson's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Huntington's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of amyotrophic lateral sclerosis; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Alzheimer's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Tourette Syndrome; pharmaceutical preparations and substances for the prevention, treatment and alleviation of epilepsy; pharmaceutical preparations and substances for the prevention, treatment and alleviation of multiple sclerosis; pharmaceutical preparations and substances for the prevention, treatment and alleviation of cardio-pulmonary disorders, diseases, conditions, and ailments; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions, and ailments of the circulatory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension, high blood pressure, heart failure and ventricular dysfunction; pharmaceutical preparations and substances for the prevention, treatment and alleviation of viral and infectious diseases; pharmaceutical preparations and substances for the prevention, treatment and alleviation of central nervous system disorders, diseases, conditions and ailments, namely, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, cerebral palsy, insomnia, mood disorders, bipolar disorder, seizure disorders; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the respiratory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the endocrine system; pharmaceutical preparations for the treatment of immunologic diseases, namely, auto immune motility diseases, immunologic deficiency syndromes, auto immune diseases, Acquired Immune Deficiency Syndrome (AIDS), hypersensitivity, allergies, tumors of the immunological organs; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the musculoskeletal system, namely, bone diseases and bone degenerative conditions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for the treatment of polycystic ovary syndrome; pharmaceutical preparations and substances for the treatment of infertility; pharmaceutical preparations and substances for the treatment of diabetes; pharmaceutical preparations and substances for the treatment of heart disease; pharmaceutical preparations and substances for the treatment of pain; pharmaceutical preparations and substances for the treatment of cardiovascular disease; pharmaceutical preparations and substances for the treatment of depression and social anxiety; pharmaceutical preparations and substances for the treatment of insomnia; pharmaceutical preparations and substances for the treatment of sleep disorders; pharmaceutical preparations and substances for the treatment of migraine and neurological disorders; Veterinary products, namely, veterinary preparations for dogs, cats and horses for use during ophthalmic surgery and recovery therefrom; eye drops for veterinary use; Pharmaceutical preparations for the treatment of cancer, neurological and dermatological disorders; pharmaceutical preparations for the treatment of myasthenia gravis, depression, mood/anxiety conditions, solar keratoses and cancer; antidepressants; tranquilizers; nasal spray preparations; Pharmaceutical preparations for the treatment of neuromuscular conditions; Pharmaceutical preparations, namely, retinoids, for the treatment of skin related diseases, cancer and precancerous conditions, and disorders related to the modulation of apoptosis; vitamin supplement distributed by prescription only; pharmaceutical preparations, namely, an oral glucose gel for the treatment of low blood sugar; pharmaceutical preparation for the treatment of headaches; pharmaceutical preparations, namely, diazepam rectal gel; Methyltestosterone for use in the treatment of hormone deficiencies; medicated skin lotion for the relief of itch caused by insect bites, eczema, sunburn and poison ivy; Dressings for wounds; Preparations and substances for the relief of anorectal discomfort, inflammation, and irritation; hemorrhoidal suppositories; Pharmaceutical preparations for the treatment of irritable bowel syndrome; Drugs to treat opioid-induced constipation; Psychotropic preparations; Cough medicine in the nature of a saline solution, namely, a spray for nasal dryness due to allergies, cold and flu; Medicated eye wash; Eye drops containing antihistamines and decongestants; Pharmaceutical preparations, namely, an ophthalmic preparation for use in eye examinations; Pharmaceuticals preparation that operates physiologically to control skin pigmentation; Pharmaceutical preparations for wounds; pharmaceutical steroid preparations for topical use; Pharmaceutical preparations, namely, antiemetics; Preparations for use in cleaning contact lenses and kits containing said preparations | ACTIVE | — |
| 009 | Contact lenses; software for use in ophthalmic medical and surgical procedures, namely, for swept source optical coherence tomography; magnifiers, namely, magnifying lenses; software used in ophthalmological and optometric instruments, namely, corneal topographer, aberrometer and lasers, all sold as a unit and used for the diagnosis of eye conditions and vision correction; Carrying cases and containers for contact lenses; eyeglass chains; eyeglass cords; Contact lens cases; Plastic blanks, namely, optical lens blanks made of plastic for contact lenses; computer network consisting of a network server and network operating software allowing for the calculation, transfer and storage of data between components of ophthalmic, eye and vision correction systems and the customer support service provider | ACTIVE | — |
| 010 | Cosmetic apparatus, namely, light-based devices providing mainly pulsed light for performing non-ablative aesthetic skin treatment procedures; Surgical and medical apparatus and instruments for use in ophthalmic medical and surgical procedures, namely, curved patient interface and suction clip; Surgical, medical, and veterinary apparatus and instruments, namely, medical device intended to be used as intraocular lens in order to replace the natural crystalline lens of the eye during cataract surgery; artificial limbs, and teeth; surgical instruments, namely, endoscopes; disposable surgical instruments, other than for the dental sector; Veterinary implants consisting primarily of artificial materials; artificial corneal lenses for veterinary use; veterinary lens extractors; veterinary instruments, namely, slit lamps, ophthalmoscopes, tonometers, veterinary ultrasound apparatus, micro-surgical instruments, tension ring injectors, and surgical sewing material, namely, needles and sutures; surgical instruments, namely, an ultrasonic surgical system consisting of an ultrasonic surgical instrument to separate, fragment, and coagulate tissue, surgical irrigators and aspirators for medical use and related equipment, namely, a precision fluid delivery system comprised of a pump, controller and surgical tubing, fluid canisters, ultrasonic medical hand pieces, probes and cannulas sold, leased or licensed separately or as a unit; Medical devices, namely, finger-attached ultrasonic probes for diagnostic medical imaging; Kit containing one or more surgical instruments, namely, cannulae or ultrasonic probes, and a sterilization tray that holds the instruments; respiratory apparatus for medical use; drug delivery device sold empty; intraocular lenses; phacoemulsification apparatus and instruments for use in ophthalmic surgical procedures; Ophthalmic medical and surgical apparatus, equipment and instruments, namely, intraocular lenses, haptics for mounting intraocular lenses, and parts, components and fittings for the aforementioned goods; Ophthalmic medical and surgical apparatus, equipment and instruments, namely, intraocular lenses, folding intraocular lenses, and parts, components and fittings for the aforementioned goods; Lasers for medical use; Lasers for ophthalmic medical and surgical procedures; ophthalmic surgical device used to inject intraocular lenses, and intraocular lenses; Single-use ocular syringe preloaded with a capsular tension ring for use in cataract surgery; surgical instrument, namely, a vitreous cutter; Ophthalmic surgical instruments and devices used in performing ophthalmic surgical procedures, and component parts thereof; ophthalmic medical devices, namely, intraocular lenses; Medical device, namely, prosthetic intraocular implant; Line of surgical blades for use in ophthalmic surgery; Lasers for the medical and cosmetic treatment of the face and skin; Medical devices for non-surgical cosmetic skin treatments; Medical devices for contracting skin, body sculpting, and soft tissue reconstruction in a non-invasive manner; Medical devices, namely, medical instruments for the non-invasive removal of human body fat utilizing an external energy source; Surgical fat-collection canister kit consisting of a canister and a canister base assembly, a canister lid assembly, one or more ports, and one or more syringe caps; Surgical instruments for fragmentation, cutting, coagulation, aspiration and irrigation; Medical aesthetic devices that administer a combination of pneumatic energy and broadband light or pneumatic energy or broadband light alone for skin treatment and hair removal; Medical devices, namely, lasers, radio frequency, ultrasound and thermal devices for use in connection with non-surgical cosmetic skin treatment systems; Medical devices, namely, phototherapeutic apparatus for medical purposes, namely, devices for use in the treatment of dermatological conditions including acne; microsurgical instruments used in ophthalmic procedures to remove cataracts; medical and surgical instruments and apparatus, namely, a vacuum and fluid control system consisting of pumps, tubing, sensors, valves, needles, sleeves, fluid collection containers, and recipient connections; secure tubing connection device used with and in ophthalmic, ocular, cataract and eye-related surgical procedures; surgical instruments, namely, surgical needles for ophthalmic surgery; Medical devices, namely, impregnated cellulosic fiber strips for use in ophthalmic diagnosis; Surgical, medical apparatus and instruments used in performing ophthalmic, ocular and eye-related surgery, namely, knives and cutters, all of the preceding to exclude non-ophthalmic surgical, medical apparatus and instruments; Medical devices, namely, single-use injector and capsular tension ring; Keratome blades, namely, knives, namely, medical and surgical knives for cutting human or animal tissue and organs; ophthalmic and optometric instruments for making both measurements of surfaces of the eye and for performing diagnosis of the eye | ACTIVE | — |
| 044 | Cosmetic treatment services, namely, the non-invasive removal of human body fat utilizing an external energy source; Cosmetic treatment services, namely, skin care, body care and face care services; Providing a website featuring medical information in the field of pharmaceutical preparations and substances for the treatment of skin disorders, diseases, and conditions and ailments, and providing medical information related to chronic pain due to irritable bowel syndrome with diarrhea, opioid-induced constipation, and ulcerative colitis; medical and surgical services, namely, ophthalmic, ocular and eye care medical and surgical services; Providing a website featuring information and advice in the field of health issues; Providing a website featuring information in the field of medical services relating to procedures in the nature of body contouring; Providing medical information and medical services in the field of eye care, health of the eye and ophthalmics; Providing an Internet website portal for use by healthcare professionals in the field of ophthalmology; Dermatology services; Skin massage therapy; Medical spa services, namely, non-invasive cosmetic medical services; Liposuction and surgical body shaping services; Medical services for the treatment of skin disorders; Skin health restoration medical procedures; Medical spa services, namely, cosmetic therapies; Cosmetic body care services in the nature of non-surgical body contouring; medical services, namely, skin subcutaneous tissue treatment services; aesthetic and therapeutic skin and body treatment services; providing dermatological treatment services using lasers and radio frequency devices; providing health information; medical services, namely, orthokeratology procedures; Cosmetic and plastic surgery and dermatological treatment services; Medical services in the nature of performing ultrasonic surgical procedures; Medical procedures, namely, ultrasonic body shaping treatments; Pharmacists' services to make up prescriptions; Preparation and dispensing of medications | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Bausch & Lomb Incorporated
- Other trademarks owned by Bausch & Lomb Incorporated
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 044
- Similar marks named BAUSCH HEALTH
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 28, 2022 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Dec 21, 2022 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Dec 14, 2022 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jul 18, 2022 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 18, 2022 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 23, 2022 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Mar 9, 2022 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Nov 13, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 12, 2021 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Nov 7, 2021 | EXT5 | SOU EXTENSION 5 FILED | — |
| Nov 7, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 16, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 16, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 16, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 1, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 30, 2021 | EX4G | SOU EXTENSION 4 GRANTED | — |
| May 30, 2021 | EXT4 | SOU EXTENSION 4 FILED | — |
| May 30, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 1, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 28, 2020 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Nov 28, 2020 | EXT3 | SOU EXTENSION 3 FILED | — |
| Nov 28, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 25, 2020 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| May 19, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 15, 2020 | EX2G | SOU EXTENSION 2 GRANTED | — |
| May 15, 2020 | EXT2 | SOU EXTENSION 2 FILED | — |
| May 15, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 11, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 11, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 11, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 11, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 11, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 12, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 11, 2019 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 11, 2019 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 9, 2019 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 9, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 11, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 16, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 16, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 27, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 12, 2019 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Mar 5, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 5, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 5, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 5, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 5, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 5, 2019 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Mar 5, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 5, 2019 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jan 29, 2019 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Jan 15, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 10, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 9, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 9, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 19, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 19, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 19, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 11, 2018 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Nov 20, 2018 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Nov 8, 2018 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Nov 8, 2018 | ALIE | ASSIGNED TO LIE | — |
| Oct 24, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 24, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 24, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 24, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 24, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 23, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 22, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 22, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 15, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 15, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 15, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 9, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 13, 2018 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jun 12, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 10, 2018 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 10, 2018 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 10, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 8, 2018 | NWAP | NEW APPLICATION ENTERED | — |